{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T15:20:37Z","timestamp":1786461637614,"version":"build-2736575974"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T00:00:00Z","timestamp":1746489600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T00:00:00Z","timestamp":1746489600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s10147-025-02753-x","type":"journal-article","created":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T16:51:24Z","timestamp":1746550284000},"page":"1080-1097","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Efficacy and safety of cancer vaccine therapy in malignant melanoma: a systematic review"],"prefix":"10.1007","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3057-6284","authenticated-orcid":false,"given":"Takeshi","family":"Seta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2855-721X","authenticated-orcid":false,"given":"Shohei","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4907-4647","authenticated-orcid":false,"given":"Mitsuaki","family":"Oura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-5730-1066","authenticated-orcid":false,"given":"Kazuki","family":"Yokoyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3313-1990","authenticated-orcid":false,"given":"Yoshitaka","family":"Nishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7171-8971","authenticated-orcid":false,"given":"Nobuaki","family":"Hoshino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2134-2865","authenticated-orcid":false,"given":"Kiichiro","family":"Ninomiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3603-8575","authenticated-orcid":false,"given":"Tatsunori","family":"Shimoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0112-0843","authenticated-orcid":false,"given":"Katsuyuki","family":"Hotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7918-6252","authenticated-orcid":false,"given":"Takeo","family":"Nakayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,6]]},"reference":[{"key":"2753_CR1","doi-asserted-by":"publisher","first-page":"e15087","DOI":"10.7759\/cureus.15087","volume":"13","author":"MG Davey","year":"2021","unstructured":"Davey MG, Miller N, McInerney NM (2021) A review of epidemiology and cancer biology of malignant melanoma. Cureus 13:e15087. https:\/\/doi.org\/10.7759\/cureus.15087","journal-title":"Cureus"},{"key":"2753_CR2","unstructured":"https:\/\/www.wcrf.org\/cancer-trends\/skin-cancer-statistics\/"},{"key":"2753_CR3","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1002\/1097-0142(19840315)53:6<1299::aid-cncr2820530613>3.0.co;2-4","volume":"53","author":"GJ Hill 2nd","year":"1984","unstructured":"Hill GJ 2nd, Krementz ET, Hill HZ (1984) Dimethyl triazeno imidazole carboxamide and combination therapy for melanoma. IV. Late results after complete response to chemotherapy (Central Oncology Group protocols 7130, 7131, and 7131A). Cancer 53:1299\u20131305. https:\/\/doi.org\/10.1002\/1097-0142(19840315)53:6%3c1299::aid-cncr2820530613%3e3.0.co;2-4","journal-title":"Cancer"},{"key":"2753_CR4","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1200\/JCO.2010.32.2537","volume":"29","author":"PF Robbins","year":"2011","unstructured":"Robbins PF, Morgan RA, Feldman SA et al (2011) Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol 29:917\u2013924. https:\/\/doi.org\/10.1200\/JCO.2010.32.2537","journal-title":"J Clin Oncol"},{"key":"2753_CR5","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","volume":"364","author":"PB Chapman","year":"2011","unstructured":"Chapman PB, Hauschild A, Robert C et al (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364:2507\u20132516. https:\/\/doi.org\/10.1056\/NEJMoa1103782","journal-title":"N Engl J Med"},{"key":"2753_CR6","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","volume":"33","author":"RH Andtbacka","year":"2015","unstructured":"Andtbacka RH, Kaufman HL, Collichio F et al (2015) Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol 33:2780\u20132788. https:\/\/doi.org\/10.1200\/JCO.2014.58.3377","journal-title":"J Clin Oncol"},{"key":"2753_CR7","unstructured":"Tamemasa D (2014) Novel immunotherapy in oncology. In: Furue M (ed) Malignant tumors of the skin: latest advances in diagnosis and treatment for practical applications. Nakayama, Shoten (in Japanese)"},{"key":"2753_CR8","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1038\/nm1100","volume":"10","author":"SA Rosenberg","year":"2004","unstructured":"Rosenberg SA, Yang JC, Restifo NP (2004) Cancer immunotherapy: moving beyond current vaccines. Nat Med 10:909\u2013915. https:\/\/doi.org\/10.1038\/nm1100","journal-title":"Nat Med"},{"key":"2753_CR9","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71","journal-title":"BMJ"},{"key":"2753_CR10","unstructured":"Japan Clinical Oncology Society (2023) (ed) Guidelines for Cancer Immunotherapy, 3rd edition. Kanehara Shuppan, Tokyo (in Japanese)"},{"key":"2753_CR11","unstructured":"Japan Clinical Oncology Society (2019) (ed) Guidelines for Cancer Immunotherapy, 2nd edn. Kanehara Shuppan, Tokyo (in Japanese)"},{"key":"2753_CR12","unstructured":"Japan Clinical Oncology Society (2016) (ed) Guidelines for cancer immunotherapy, 1st edn. Kanehara Shuppan, Tokyo (in Japanese)"},{"key":"2753_CR13","doi-asserted-by":"crossref","unstructured":"Young T, Hopewell S (2011) Methods for obtaining unpublished data. Cochrane Database Syst Rev 11:MR000027","DOI":"10.1002\/14651858.MR000027.pub2"},{"key":"2753_CR14","doi-asserted-by":"crossref","unstructured":"Higgins JP, Altman DG, G\u00f8tzsche PC, Cochrane Bias Methods Group, Cochrane Statistical Methods Group et al (2011) The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ 343:d5928","DOI":"10.1136\/bmj.d5928"},{"key":"2753_CR15","unstructured":"Fagerlin A (2011) \u201cChapter 7: quantitative information\u201d. In: Fischhoff B, Brewer NT, Downs JS (eds) Communicating risks and benefits: an evidence-based User\u2019s Guide, pp 57\u201361. Annapolis: Food and Drug Administration (FDA).\u00a0http:\/\/www.fda.gov\/downloads\/AboutFDA\/ReportsManualsForms\/Reports\/UCM268069.pdf"},{"key":"2753_CR16","doi-asserted-by":"publisher","first-page":"916","DOI":"10.7326\/0003-4819-117-11-916","volume":"117","author":"CD Naylor","year":"1992","unstructured":"Naylor CD, Chen E, Strauss B (1992) Measured enthusiasm: does the method of reporting trial results alter perceptions of therapeutic effectiveness? Ann Intern Med 117:916\u2013921","journal-title":"Ann Intern Med"},{"key":"2753_CR17","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ et al (2003) Measuring incomsistency in meta-analysis. BMJ 327:557\u2013560","journal-title":"BMJ"},{"key":"2753_CR18","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177\u2013188","journal-title":"Control Clin Trials"},{"key":"2753_CR19","doi-asserted-by":"publisher","DOI":"10.4159\/9780674040243","volume-title":"Summing up: the science of reviewing research","author":"RJ Light","year":"1984","unstructured":"Light RJ, Pilemer DB (1984) Summing up: the science of reviewing research. Harvard University Press, Cambridge"},{"key":"2753_CR20","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.2307\/2533446","volume":"50","author":"CB Begg","year":"1994","unstructured":"Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50:1088\u20131101","journal-title":"Biometrics"},{"key":"2753_CR21","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M et al (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629\u2013634","journal-title":"BMJ"},{"key":"2753_CR22","volume-title":"Stata Statistical Software: Release 17","author":"StataCorp","year":"2022","unstructured":"StataCorp (2022) Stata Statistical Software: Release 17. StataCorp LP, College Station"},{"key":"2753_CR23","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/bjc.1976.140","volume":"34","author":"ES Newlands","year":"1976","unstructured":"Newlands ES, Oon CJ, Roberts JT et al (1976) Clinical trial of combination chemotherapy and specific active immunotherapy in disseminated melanoma. Br J Cancer 34:174\u2013179. https:\/\/doi.org\/10.1038\/bjc.1976.140","journal-title":"Br J Cancer"},{"key":"2753_CR24","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1200\/JCO.1994.12.5.1036","volume":"12","author":"PO Livingston","year":"1994","unstructured":"Livingston PO, Wong GY, Adluri S et al (1994) Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol 12:1036\u20131044. https:\/\/doi.org\/10.1200\/JCO.1994.12.5.1036","journal-title":"J Clin Oncol"},{"key":"2753_CR25","doi-asserted-by":"publisher","first-page":"2370","DOI":"10.1200\/JCO.2001.19.9.2370","volume":"19","author":"JM Kirkwood","year":"2001","unstructured":"Kirkwood JM, Ibrahim JG, Sosman JA et al (2001) High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH\/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694\/S9512\/C509801. J Clin Oncol 19:2370\u20132380. https:\/\/doi.org\/10.1200\/JCO.2001.19.9.2370","journal-title":"J Clin Oncol"},{"key":"2753_CR26","first-page":"1882","volume":"7","author":"JC Bystryn","year":"2001","unstructured":"Bystryn JC, Zeleniuch-Jacquotte A, Oratz R et al (2001) Double-blind trial of a polyvalent, shed-antigen, melanoma vaccine. Clin Cancer Res 7:1882\u20131887","journal-title":"Clin Cancer Res"},{"key":"2753_CR27","doi-asserted-by":"publisher","first-page":"4181","DOI":"10.1200\/JCO.2002.12.094","volume":"20","author":"P Hersey","year":"2002","unstructured":"Hersey P, Coates AS, McCarthy WH et al (2002) Adjuvant immunotherapy of patients with high-risk melanoma using vaccinia viral lysates of melanoma: results of a randomized trial. J Clin Oncol 20:4181\u20134190. https:\/\/doi.org\/10.1200\/JCO.2002.12.094","journal-title":"J Clin Oncol"},{"key":"2753_CR28","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1093\/annonc\/mdj138","volume":"17","author":"D Schadendorf","year":"2006","unstructured":"Schadendorf D, Ugurel S, Schuler-Thurner B et al (2006) Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG. Ann Oncol 17:563\u2013570. https:\/\/doi.org\/10.1093\/annonc\/mdj138","journal-title":"Ann Oncol"},{"key":"2753_CR29","doi-asserted-by":"publisher","unstructured":"et al (2007) Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon Alfa-2b compared with high-dose interferon Alfa-2b for Resected stage III cutaneous melanoma. J Clin Oncol 25:2078-2085. https:\/\/doi.org\/10.1200\/JCO.2006.10.1709","DOI":"10.1200\/JCO.2006.10.1709"},{"key":"2753_CR30","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1200\/JCO.2007.11.9941","volume":"26","author":"A Testori","year":"2008","unstructured":"Testori A, Richards J, Whitman E et al (2008) Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician\u2019s choice of treatment for stage IV melanoma: the C-100\u201321 Study Group. J Clin Oncol 26:955\u2013962. https:\/\/doi.org\/10.1200\/JCO.2007.11.9941","journal-title":"J Clin Oncol"},{"key":"2753_CR31","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, O\u2019Day SJ, McDermott DF et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711\u2013723. https:\/\/doi.org\/10.1056\/NEJMoa1003466","journal-title":"N Engl J Med"},{"key":"2753_CR32","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1056\/NEJMoa1012863","volume":"364","author":"DJ Schwartzentruber","year":"2011","unstructured":"Schwartzentruber DJ, Lawson DH, Richards JM et al (2011) gp100 Peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med 364:2119\u20132127. https:\/\/doi.org\/10.1056\/NEJMoa1012863","journal-title":"N Engl J Med"},{"key":"2753_CR33","doi-asserted-by":"publisher","first-page":"3831","DOI":"10.1200\/JCO.2012.47.9303","volume":"31","author":"AM Eggermont","year":"2013","unstructured":"Eggermont AM, Suciu S, Rutkowski P et al (2013) Adjuvant ganglioside GM2-KLH\/QS-21 vaccination versus observation after resection of primary tumor > 1.5 mm in patients with stage II melanoma: results of the EORTC 18961 randomized phase III trial. J Clin Oncol 31:3831\u20133837. https:\/\/doi.org\/10.1200\/JCO.2012.47.9303","journal-title":"J Clin Oncol"},{"key":"2753_CR34","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1097\/COC.0b013e318277d5c8","volume":"37","author":"G Jha","year":"2014","unstructured":"Jha G, Miller JS, Curtsinger JM et al (2014) Randomized phase II study of IL-2 with or without an allogeneic large multivalent immunogen vaccine for the treatment of stage IV melanoma. Am J Clin Oncol 37:261\u2013265. https:\/\/doi.org\/10.1097\/COC.0b013e318277d5c8","journal-title":"Am J Clin Oncol"},{"key":"2753_CR35","doi-asserted-by":"publisher","first-page":"4066","DOI":"10.1200\/JCO.2015.62.0500","volume":"33","author":"DH Lawson","year":"2015","unstructured":"Lawson DH, Lee S, Zhao F et al (2015) Randomized, placebo-controlled, phase III trial of yeast-derived granulocyte-macrophage colony-stimulating factor (GM-CSF) versus peptide vaccination versus GM-CSF plus peptide vaccination versus placebo in patients with no evidence of disease after complete surgical resection of locally advanced and\/or stage IV melanoma: a trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E4697). J Clin Oncol 33:4066\u20134076. https:\/\/doi.org\/10.1200\/JCO.2015.62.0500","journal-title":"J Clin Oncol"},{"key":"2753_CR36","doi-asserted-by":"publisher","first-page":"3991","DOI":"10.1245\/s10434-017-6072-3","volume":"24","author":"MB Faries","year":"2017","unstructured":"Faries MB, Mozzillo N, Kashani-Sabet M et al (2017) Long-term survival after complete surgical resection and adjuvant immunotherapy for distant melanoma metastases. Ann Surg Oncol 24:3991\u20134000. https:\/\/doi.org\/10.1245\/s10434-017-6072-3","journal-title":"Ann Surg Oncol"},{"key":"2753_CR37","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1016\/S1470-2045(18)30254-7","volume":"19","author":"B Dreno","year":"2018","unstructured":"Dreno B, Thompson JF, Smithers BM et al (2018) MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol 19:916\u2013929. https:\/\/doi.org\/10.1016\/S1470-2045(18)30254-7","journal-title":"Lancet Oncol"},{"key":"2753_CR38","doi-asserted-by":"publisher","first-page":"2589","DOI":"10.1007\/s00262-020-02618-4","volume":"69","author":"Y Jansen","year":"2020","unstructured":"Jansen Y, Kruse V, Corthals J et al (2020) A randomized controlled phase II clinical trial on mRNA electroporated autologous monocyte-derived dendritic cells (TriMixDC-MEL) as adjuvant treatment for stage III\/IV melanoma patients who are disease-free following the resection of macrometastases. Cancer Immunol Immunother 69:2589\u20132598. https:\/\/doi.org\/10.1007\/s00262-020-02618-4","journal-title":"Cancer Immunol Immunother"},{"key":"2753_CR39","doi-asserted-by":"publisher","first-page":"e000410","DOI":"10.1136\/jitc-2019-000410","volume":"8","author":"JS Cebon","year":"2020","unstructured":"Cebon JS, Gore M, Thompson JF et al (2020) Results of a randomized, double-blind phase II clinical trial of NY-ESO-1 vaccine with ISCOMATRIX adjuvant versus ISCOMATRIX alone in participants with high-risk resected melanoma. J Immunother Cancer 8:e000410. https:\/\/doi.org\/10.1136\/jitc-2019-000410","journal-title":"J Immunother Cancer"},{"key":"2753_CR40","doi-asserted-by":"publisher","first-page":"4302","DOI":"10.1002\/cam4.3969","volume":"10","author":"RC Chick","year":"2021","unstructured":"Chick RC, Faries MB, Hale DF et al (2021) Multi-institutional, prospective, randomized, double-blind, placebo-controlled phase IIb trial of the tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine to prevent recurrence in high-risk melanoma patients: a subgroup analysis. Cancer Med 10:4302\u20134311. https:\/\/doi.org\/10.1002\/cam4.3969","journal-title":"Cancer Med"},{"key":"2753_CR41","doi-asserted-by":"publisher","first-page":"6126","DOI":"10.1245\/s10434-021-09709-1","volume":"28","author":"TJ Vreeland","year":"2021","unstructured":"Vreeland TJ, Clifton GT, Hale DF et al (2021) A phase IIb randomized controlled trial of the TLPLDC vaccine as adjuvant therapy after surgical resection of stage III\/IV melanoma: a primary analysis. Ann Surg Oncol 28:6126\u20136137. https:\/\/doi.org\/10.1245\/s10434-021-09709-1","journal-title":"Ann Surg Oncol"},{"key":"2753_CR42","doi-asserted-by":"publisher","first-page":"842555","DOI":"10.3389\/fimmu.2022.842555.eCollection","volume":"13","author":"A Mordoh","year":"2022","unstructured":"Mordoh A, Aris M, Carri I et al (2022) An update of cutaneous melanoma patients treated in adjuvancy with the allogeneic melanoma vaccine VACCIMEL and presentation of a selected case report with in-transit metastases. Front Immunol 13:842555. https:\/\/doi.org\/10.3389\/fimmu.2022.842555.eCollection","journal-title":"Front Immunol"},{"key":"2753_CR43","doi-asserted-by":"publisher","first-page":"2694","DOI":"10.1093\/annonc\/mdt291","volume":"24","author":"D McDermott","year":"2013","unstructured":"McDermott D, Haanen J, Chen TT et al (2013) Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20). Ann Oncol 24:2694\u20132698. https:\/\/doi.org\/10.1093\/annonc\/mdt291","journal-title":"Ann Oncol"},{"key":"2753_CR44","doi-asserted-by":"publisher","first-page":"625","DOI":"10.3389\/fimmu.2017.00625","volume":"8","author":"J Mordoh","year":"2017","unstructured":"Mordoh J, Pampena MB, Aris M et al (2017) Phase II study of adjuvant immunotherapy with the CSF-470 vaccine plus bacillus calmette-guerin plus recombinant human granulocyte macrophage-colony stimulating factor vs medium-dose interferon alpha 2B in stages IIB, IIC, and III cutaneous melanoma patients: a single institution. Randomized Study Front Immunol 8:625. https:\/\/doi.org\/10.3389\/fimmu.2017.00625","journal-title":"Randomized Study Front Immunol"},{"key":"2753_CR45","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1200\/JCO.22.00343","volume":"41","author":"JA Chesney","year":"2023","unstructured":"Chesney JA, Ribas A, Long GV et al (2023) Randomized, double-blind, placebo-controlled, global phase III trial of talimogene laherparepvec combined with pembrolizumab for advanced melanoma. J Clin Oncol 41:528\u2013540","journal-title":"J Clin Oncol"},{"key":"2753_CR46","doi-asserted-by":"publisher","first-page":"e006270","DOI":"10.1136\/jitc-2022-006270","volume":"11","author":"JA Chesney","year":"2023","unstructured":"Chesney JA, Puzanov I, Collichio FA et al (2023) Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open-label, phase II trial. J Immunother Cancer 11:e006270","journal-title":"J Immunother Cancer"},{"key":"2753_CR47","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/S0140-6736(23)02268-7","volume":"403","author":"JS Weber","year":"2024","unstructured":"Weber JS, Carlino MS, Khattak A et al (2024) Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study. Lancet 403:632\u2013644. https:\/\/doi.org\/10.1016\/S0140-6736(23)02268-7","journal-title":"Lancet"},{"key":"2753_CR48","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/d41573-023-00118-5","volume":"22","author":"E Dolgin","year":"2023","unstructured":"Dolgin E (2023) Personalized cancer vaccines pass first major clinical test. Nat Rev Drug Discov 22:607\u2013609. https:\/\/doi.org\/10.1038\/d41573-023-00118-5","journal-title":"Nat Rev Drug Discov"},{"key":"2753_CR49","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/s41392-023-01674-3","volume":"8","author":"T Fan","year":"2023","unstructured":"Fan T, Zhang M, Yang J et al (2023) Therapeutic cancer vaccines: advancements, challenges, and prospects. Signal Transduct Target Ther 8:450. https:\/\/doi.org\/10.1038\/s41392-023-01674-3","journal-title":"Signal Transduct Target Ther"},{"key":"2753_CR50","doi-asserted-by":"publisher","first-page":"121","DOI":"10.7326\/0003-4819-151-2-200907210-00009","volume":"151","author":"L Fuccio","year":"2009","unstructured":"Fuccio L, Zagari RM, Eusebi LH et al (2009) Meta-analysis: can Helicobacter pylori eradication treatment reduce the risk for gastric cancer? Ann Intern Med 151:121\u2013128","journal-title":"Ann Intern Med"},{"key":"2753_CR51","doi-asserted-by":"publisher","first-page":"e0183321","DOI":"10.1371\/journal.pone.0183321","volume":"12","author":"T Seta","year":"2017","unstructured":"Seta T, Takahashi Y, Noguchi Y et al (2017) Effectiveness of Helicobacter pylori eradication in the prevention of primary gastric cancer in healthy asymptomatic people: a systematic review and meta-analysis comparing risk ratio with risk difference. PLoS ONE 12:e0183321","journal-title":"PLoS ONE"},{"key":"2753_CR52","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1080\/00031305.2016.1154108","volume":"70","author":"RL Wasserstein","year":"2016","unstructured":"Wasserstein RL, Lazar NA (2016) The ASA statement on p-values: context, process, and purpose. Am Statistician 70:129\u2013133","journal-title":"Am Statistician"},{"key":"2753_CR53","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1002\/jgf2.306","volume":"21","author":"T Seta","year":"2020","unstructured":"Seta T, Takahashi Y, Yamashita Y et al (2020) Outcome measures reported in abstracts of randomized controlled trials in leading clinical journals: a bibliometric study. J Gen Fam Med 21:119\u2013126","journal-title":"J Gen Fam Med"},{"key":"2753_CR54","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1056\/NEJMoa2210233","volume":"387","author":"MW Rohaan","year":"2022","unstructured":"Rohaan MW, Borch TH, van den Berg JH et al (2022) Tumor-infiltrating lymphocyte therapy or ipilimumab in advanced melanoma. N Engl J Med 387:2113\u20132125","journal-title":"N Engl J Med"},{"key":"2753_CR55","unstructured":"https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-cellular-therapy-treat-patients-unresectable-or-metastatic-melanoma"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02753-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-025-02753-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02753-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T05:11:04Z","timestamp":1748495464000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-025-02753-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,6]]},"references-count":55,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["2753"],"URL":"https:\/\/doi.org\/10.1007\/s10147-025-02753-x","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,6]]},"assertion":[{"value":"30 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Hotta reports honoraria from AstraZeneca, Chugai, Lilly, MSD, BMS, Ono, Boehringer Ingelheim, NipponKayaku, Amgen, Taiho, and Merck, and research grants from MSD, AstraZeneca, Chugai, Lilly, BMS, Abbvie, and Ono. Dr. Nakayama reports personal fees from Pharmaceutical Co.; Johnson & Johnson K.K.; AstraZeneca plc; Nippon Zoki Pharmaceutical Co., Ltd.; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: Pfizer Japan Inc.; MSD K.K.; Chugai Pharamaceutical Co.; Takeda Pharmaceutical Co.; Janssen Pharmaceutical K.K.; Boehringer Ingelheim International GmbH.; Eli Lilly Japan K.K.; Maruho Co., Ltd.; Mitsubishi Tanabe Pharma Co.; Novartis Pharma K.K.; Allergan Japan K.K.; Novo Nordisk Pharma Ltd.; TOA EIYO Ltd.; AbbVie Inc.; ONO PHARMACEUTICAL CO., LTD.;GSK plc; Alexion Pharmaceuticals, Inc.; Cannon Medical Systems Co.; Kowa Company, Limited; Araya; Merck Co.;\u00a0Amicus Therapeutics, Inc.; Merck Co.; stock options: BonBon inc.; donation: CancerScan; JMDC Inc. All of them were outside the submitted work. Other authors have stated explicitly that there are no conflicts of interest in connection with this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}